Polypoidal choroidal vasculopathy (PCV) is a hemorrhagic and exudative maculopathy characterized by hyalinization and peripapillary, macular or peripheral sub-retinal pigment epithelium (RPE) polypoidal dilatations of branching choroidal vascular networks in indocyanine green angiography (ICGA) presentations[@b1][@b2][@b3], which may subsequently lead to detachments of RPE, or even neurosensory retina[@b2][@b4][@b5][@b6][@b7]. Due to the many shared clinical hallmarks with age-related macular degeneration (AMD), including recurrent subretinal hemorrhage, exudation, serous and hemorrhagic RPE detachment, and vitreous hemorrhage, PCV remains unrecognized for a long period until its first identification by Yannuzzi et al in 1990[@b2]. Recent studies indicate more unique manifestations in PCV that distinguished PCV from AMD, suggesting that PCV is a clinical entity separated from AMD[@b1][@b8][@b9].

The pathogenesis of PCV remains elusive, while it is widely accepted that both genetic and environmental factors play important roles in the disease course of PCV. Considering the clinical similarities between AMD and PCV, researchers aim to find out whether AMD and PCV share common pathogenic pathways. Previous meta-analyses have reported that age-related maculopathy susceptibility 2 (*ARMS2*; MIM: 611313) rs10490924 and complement factor H (*CFH*; MIM: 134370) rs800292 polymorphisms, variants implicated in AMD etiology, might also increase PCV risk[@b10][@b11]. The complement component 2 (*C2*; MIM: 613927) rs547154 variant is a G to T substitution located on chromosome 6p21, which shows protective effect against AMD[@b12][@b13]. This variant has been widely investigated for its association with PCV[@b14][@b15][@b16][@b17][@b18], while the results are controversial and the sample size in each study is limited. Therefore, we performed this meta-analysis to assess the relationship between the *C2* variant and PCV susceptibility.

Results
=======

Literature
----------

The initial literature search yielded 97 articles relevant to the search terms. Five articles, published from 2008 to 2014, embodying 4076 subjects (1220 PCV cases, 1073 AMD cases and 1783 controls) were finally included for the meta-analysis[@b14][@b15][@b16][@b17][@b18]. Flow chart of literature screening and review was shown in [Figure 1](#f1){ref-type="fig"}. All five were case-control studies in English with their characteristics listed in [Table 1](#t1){ref-type="table"}. The average ages ranged from 63.80 to 73.00 years in the PCV case group, from 73.60 to 75.59 years in the AMD case group, and from 48.22 to 72.90 years in the control group, while the gender ratios (male/female) in the three groups varied from 1.39 (32/23) to 3.39 (105/31) for PCV cases, 2.64 (330/125) to 2.97 (187/63) for AMD cases, and 0.67 (110/164) to 1.51 (110/73) for controls ([Table 1](#t1){ref-type="table"}). Of the 5 studies, 3 were in Japan[@b15][@b17][@b18], 1 was in Singapore[@b14], and another one was in USA[@b16]. Three studies used TaqMan for genotyping[@b15][@b17][@b18] and one used Sanger sequencing[@b14], whereas both polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and TaqMan were applied in the study performed by Lima et al[@b16].

Meta-analysis
-------------

Allelic and genotypic distributions for the *C2* rs547154 variant from each individual study are presented in [Table 2](#t2){ref-type="table"}. The genotypic distribution in the control group was consistent with Hardy-Weinberg equilibrium (HWE) in each study. The adjusted odds ratios (OR) with their 95% confidence interval (CI) and the corresponding adjusted variables were provided by two studies and were listed in [Table 2](#t2){ref-type="table"}[@b17][@b18]. Quality assessments of all included studies with the Newcastle-Ottawa Scale were included in [Table S1](#s1){ref-type="supplementary-material"}.

In the random-effect model, the pooled OR for the risk allele T versus the wild type G was 0.64 (95% CI, 0.52--0.80; *p* \< 0.0001) ([Figure 2A](#f2){ref-type="fig"}), pooled OR for genotype TT versus GG was 0.43 (95% CI, 0.15--1.26; *p*, 0.123), pooled OR for genotype TG versus GG was 0.65 (95% CI, 0.52--0.83; *p*, 0.0004), pooled OR for genotype TT + TG versus GG was 0.64 (95% CI, 0.51--0.80; *p*, 0.0002), and pooled OR for genotype TT versus TG + GG was 0.46 (95% CI, 0.16--1.34; *p*, 0.154) ([Table 3](#t3){ref-type="table"}). No significant heterogeneities exist within all five comparison groups, and results from the fixed-effect model kept consistent with the random-effect model. To minimize the bias, we used adjusted data for better estimation, and the adjusted OR for T versus G was 0.56 (95% CI, 0.42--0.74; *p* \< 0.0001) ([Figure 2B](#f2){ref-type="fig"}). No difference in allelic frequency was found between the PCV and AMD groups (OR, 0.86; 95% CI, 0.64--1.16; *p*, 0.32) ([Figure 2C](#f2){ref-type="fig"}). Subgroup analysis based on ethnicity revealed that results from both the Asian and the Caucasian groups kept consistent with overall data in all five tested models, suggesting no existed ethnic divergence ([Table 3](#t3){ref-type="table"}). Sensitivity analysis was applied to estimate the influence of each study on the pooled OR. No individual study was found to affect the result in all comparison groups, which further proved the robustness of our data. Further, no publication bias was detected via Begg\'s funnel plot and Egger\'s test.

Discussion
==========

Inconsistencies exist in the association between *C2* rs547154 polymorphism and PCV risk, suggesting the necessity to perform an exhaustive review and quantitative analysis on all evidence to determine the effect. In the present study, to assess the association between *C2* rs547154 polymorphism and PCV risk, we reviewed a total of 97 published reports and completed an analysis on 4076 subjects from 5 original studies. Our result suggests that *C2* rs547154 has protective effect on PCV in all populations.

The *C2* locus and the *CFB* locus are located closely together on chromosome 6p[@b19]. Primary structure of the *C2* gene showed 39% sequence identity with its functionally analogous complement factor B (*CFB*; MIM: 138470)[@b20]. Component C2, protein encoded by the *C2* gene, shows a wide expression in the neural retina, RPE, and choroid. C2 is part of the classical pathway of the complement system. Upon the binding with component C4b, component C2 is cleaved by activated factor component C1 into two fragments, C2b and C2a[@b21]. The former fragment, C2b, then combines with the complement factor C4b to generate the C3/C5 convertase. Mutations in *C2* have been implicated in causing complement component 2 deficiency (C2D; MIM: 217000)[@b22][@b23], whereas the functional role of *C2* in the etiology of PCV and AMD has not been fully elucidated. Thus, more functional investigations are warranted to give a better insight into the relationship between the *C2* variant and PCV.

To enhance the reliability of our results, we adopted the quality assessment tool recommended by the Newcastle-Ottawa Scale (NOS) for case-control studies. No language limitation was applied. Only studies published in peer-reviewed journals were included. In addition, we also used adjusted data for better estimation of the association. The association between *C2* rs547154 polymorphism and PCV susceptibility has been discussed in a previous report, while they have only included 3 studies and tested the allele model (T versus G)[@b24]. Several limitations of the present study should be acknowledged. The number of included studies was quite limited, and only one report was on Caucasians. Meanwhile, one study was not included due to the lack of allelic and genotypic data[@b25]. Therefore, more investigations are warranted to confirm the conclusion, especially in Caucasians and other populations. Despite our effort to narrow down the influence of other risk factors using adjusted data, the number of studies providing adjusted data, especially multivariate-adjusted data, was quite limited. We only conducted subgroup analysis on ethnicity, while the effects of age and gender were not evaluated due to the incomplete data in the control group.

In conclusion, our study suggests that the *C2* rs547154 variant shows a protective effect on the development of PCV. No significant difference was detected between the allelic frequencies in the PCV and the AMD groups. More epidemiological and biological studies are needed to ascertain the association, and to help to understand the molecular basis behind this association.

Methods
=======

Literature Searching and Study Eligibility
------------------------------------------

This meta-analysis was performed according to the PRISMA guidelines[@b26]. We searched MEDLINE, EMBASE, Web of Science, and the Cochrane Library for all relevant articles using the following three main search terms as indicated previously[@b11]: (1) ((("Choroid Diseases"\[Mesh\] AND "Vascular Diseases"\[Mesh\]) AND polypoidal) OR (polypoidal choroidal vasculopathy OR PCV)) AND ((complement component 2 OR C2 OR) AND (IVS10 OR rs547154))); (2) ("polypoidal choroidal vasculopathy"/exp OR PCV AND ("complement component 2" OR C2) AND (IVS10 OR rs547154)); and (3) ((polypoidal choroidal vasculopathy) OR PCV) AND ((complement component 2 OR C2) AND (IVS10 OR rs547154)). The most recent search was performed on Nov 28, 2014. No language filters were applied. Retrieved records and eligibility status were managed using EndNote X5 software (<http://endnote.com/>).

Included studies were: (1) studies evaluating the association between *C2* rs547154 polymorphism and PCV risk; (2) genome-wide association studies, or studies of case-control, cohort or population-based epidemiologic design; (3) studies using predefined criteria and procedures for PCV and AMD diagnoses; (4) OR have been reported, or present allelic and genotypic distributions of the *C2* rs547154 variant in PCV cases and control subjects that enable calculations of the outcomes. Alleles included T and G, and genotypes covered TT, TG and GG. We excluded case reports, reviews, conference proceedings, editorials, reports with incomplete data, and only included those with the latest follow-up information for serial publications from the same research team using overlapped subjects. Our study was approved and reviewed by the institutional ethics committee of The First Affiliated Hospital of Nanjing Medical University and adhered to the tenets of the Declaration of Helsinki.

Data Collection and Quality Evaluation
--------------------------------------

Two investigators (X.C. and X.K.) independently reviewed all retrieved articles based on title, abstracts, and complete document if necessary. They also extracted data from each study separately with a customized datasheet. All data obtained from the two reviewers were compared. Disagreements were resolved through consensus with a senior reviewer (C.Z.). Data collected included: first author, year of publication, country of sample origin, ethnicity, genotyping method, demographics of subjects, average age and gender ratio of each studied group, allelic and genotypic distributions in cases and controls, adjusted OR and adjusted factors. The NOS (accessed via <http://www.ncbi.nlm.nih.gov/books/NBK35156/>) was applied for evaluation of the risk of biases for included studies.

Data Synthesis and Analysis
---------------------------

Hardy-Weinberg equilibrium was calculated using χ^2^ test to compare the genotypic frequencies of the *C2* rs547154 variant among the control subjects. Heterogeneity among studies was assessed using Cochran\'s Q statistic, and evaluated by the proportion of variation attributable to among-study heterogeneity, *I*^*2*^. Heterogeneity was determined as indicated previously[@b27].

The following five ORs and their 95% CI were calculated using both random-effect (the DerSimonian and Laird method)[@b28] and fixed-effect model (the Mantel-Haenszel method)[@b29]: T versus G (allele model), TT versus GG (homozygous model), TG versus GG (heterozygous model), TT + TG versus GG (dominant model), and TT versus TG + GG (recessive model). Subgroup analysis was performed by ethnicity. Sensitivity was used to affirm the results by removing one individual study each time. Begg\'s funnel plot[@b30] and Egger\'s test[@b31] were applied to appraise the publication bias and small-study effects. All analyses were conducted with Review Manager (version 5.2; Cochrane Collaboration, Oxford, UK; <http://ims.cochrane.org/revman>) and STATA software (version 12.0; StataCorp LP, College Station, TX). Alpha was set to 0.05 for two-sided test.
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###### Characteristics of Included Studies

  Author (Publication Year)    Region (Ethnicity)    Genotyping Method   Total (N)   Average Age (yrs)   Gender Ratio (M/F)                                                                    
  --------------------------- --------------------- ------------------- ----------- ------------------- -------------------- -------------- -------------- --------------- --------- --------- ---------
  Lee et al (2008)[@b14]       Singapore (Chinese)   Sanger sequencing      72              NA                   93           63.80 ± 7.60        NA        67.20 ± 4.60     46/26      NA       40/53
  Kondo et al (2009)[@b15]      Japan (Japanese)          TaqMan            136             NA                  183           73.00 ± 6.80        NA        72.00 ± 5.80    105/31      NA      110/73
  Lima et al (2010)[@b16]        USA (Caucasian)      PCR-RFLP/TaqMan       55              368                 368           73.00 ± 8.20        NA             NA          32/23      NA        NA
  Nakata et al (2012)[@b17]     Japan (Japanese)          TaqMan            581             455                 865           72.59 ± 8.13   75.59 ± 8.60   48.22 ± 16.18   420/161   330/125   431/434
  Tanaka et al (2014)[@b18]     Japan (Japanese)          TaqMan            376             250                 274           70.00 ± 8.90   73.60 ± 7.50   72.90 ± 7.40    266/110   187/63    110/164

Abbreviations: RFLP, restriction fragment length polymorphism; PCV: polypoidal choroidal vasculopathy; AMD: age-related macular degeneration; NA: not available; yrs: years; M/F: male/female.

###### Genotype Distribution and Allele Frequency of Included Studies

                        PCV   Control                                                                                               
  -------------------- ----- ---------- --------- ------ ----- ----------- ---------- ------- ------- --------------------- ------- ---------------------------------------------
  Lee et al[@b14]       72     0/5/67     5/139    3.47   93     0/9/84      9/177     4.84    0.624           NA             NA                         NA
  Kondo et al[@b15]     136   1/19/116   21/251    7.72   183   2/32/149     36/330    9.84    0.848           NA             NA                         NA
  Lima et al[@b16]      55     0/4/51     4/106    3.63   368   5/77/286     87/649    11.82   0.943           NA             NA                         NA
  Nakata et al[@b17]    581   2/57/522   61/1101   5.25   865   5/121/739   131/1599   7.57    0.984   0.54 \[0.35--0.84\]   0.006                    Age, Sex
  Tanaka et al[@b18]    376   1/40/335   42/710    5.59   274   4/41/229     49/499    8.94    0.179   0.48 \[0.26--0.89\]   0.018   Multiple factors[†](#t2-fn1){ref-type="fn"}

†Age, Sex, Hypertension, DM, Smoking.

Abbreviations: PCV: polypoidal choroidal vasculopathy; HWE: Hardy--Weinberg equilibrium; NA: not available; OR: odds ratio; CI: confidence interval.

###### Meta-analysis for *C2* rs547154 polymorphism and PCV risk

                                                Sample Size   Random-Effect Model    Fixed-Effect Model    Heterogeneity                                                   
  --------------------------- ------------ --- ------------- --------------------- ---------------------- --------------- ---------------------- ---------- ------ ------- -------
  T vs G (Allele)               Overall     5      2440              3566           0.64 \[0.52, 0.80\]      \<0.0001      0.63 \[0.51, 0.78\]    \<0.0001   0.00   0.536   0.425
                               East Asian   4      2330              2830           0.67 \[0.53, 0.84\]       0.0005       0.67 \[0.53, 0.84\]     0.0005    0.00   0.925   0.710
                               Caucasian    1       110               736           0.28 \[0.10, 0.78\]        0.015       0.28 \[0.10, 0.78\]     0.015      NA     NA      NA
  TT vs GG (Homozygous)         Overall     4      1028              1419           0.43 \[0.15, 1.26\]        0.123       0.42 \[0.14, 1.21\]     0.106     0.00   0.824   0.861
                               East Asian   3       977              1128           0.42 \[0.13, 1.33\]        0.140       0.40 \[0.13, 1.25\]     0.116     0.00   0.640   0.785
                               Caucasian    1       51                291           0.51 \[0.03, 9.29\]        0.646       0.51 \[0.03, 9.29\]     0.646      NA     NA      NA
  TG vs GG (Heterozygous)       Overall     5      1216              1767           0.65 \[0.52, 0.83\]       0.0004       0.64 \[0.51, 0.81\]     0.0002    0.00   0.631   0.424
                               East Asian   4      1161              1404           0.68 \[0.54, 0.87\]        0.002       0.68 \[0.54, 0.87\]     0.002     0.00   0.985   0.454
                               Caucasian    1       55                363           0.29 \[0.10, 0.83\]        0.021       0.29 \[0.10, 0.83\]     0.021      NA     NA      NA
  TT + TG vs GG (Dominant)      Overall     5      1220              1783           0.64 \[0.51, 0.80\]       0.0002       0.63 \[0.50, 0.79\]    \<0.0001   0.00   0.570   0.420
                               East Asian   4      1165              1415           0.67 \[0.53, 0.85\]       0.0009       0.67 \[0.53, 0.85\]     0.0009    0.00   0.968   0.587
                               Caucasian    1       55                368           0.27 \[0.10, 0.78\]        0.015       0.27 \[0.10, 0.78\]     0.015      NA     NA      NA
  TT vs TG + GG (Recessive)     Overall     4      1148              1690           0.46 \[0.16, 1.34\]        0.154       0.44 \[0.15, 1.28\]     0.133     0.00   0.820   0.915
                               East Asian   3      1093              1322           0.44 \[0.14, 1.39\]        0.163       0.42 \[0.14, 1.31\]     0.136     0.00   0.642   0.782
                               Caucasian    1       55                368           0.60 \[0.03, 10.92\]       0.727       0.60 \[0.03, 10.92\]    0.727      NA     NA      NA

**Abbreviations**: PCV: polypoidal choroidal vasculopathy; OR: odds ratio; CI: confidence interval.
